Mdm2 heterozygous Arf−/−p53+/− mice had a significantly protracted rate of tumor development compared to Mdm2 wild-type Arf−/−p53+/− mice, resulting in increased survival (Fig. 1B). This evidence concerns the gene MDM2 and neoplasm.